All articles by Srivari Aishwarya

Srivari Aishwarya

October’s top stories: NIH found new target proteins for anti-malaria drugs, NCI discovered new way to combat cancer

NIH found new target proteins for anti-malaria drugs and Netherlands Cancer Institute (NCI) discovered a new way to fight cancer. wraps up the key headlines from October.

UK MHRA recommends Roche’s new immunotherapy atezolizumab for bladder cancer

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given a positive scientific opinion for Roche’s new immunotherapy, atezolizumab, which is accessible for patients with an incurable form of bladder cancer.

SRI wins $150m contract to accelerate production of HIV-prevention products

US-based SRI International has been contracted by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Division of AIDS (NIAID-DAIDS) to provide development and manufacturing support for HIV microbicides and other non-vaccine pre-exposure (PreP) agents.

UK’s CMA fines Pfizer and Flynn Pharma nearly £90m for unfair pricing of epilepsy drug

Pfizer and Flynn Pharma have been fined nearly £90m by the Competition and Markets Authority (CMA) for charging unfair prices in the UK for phenytoin sodium capsules, an anti-epilepsy drug.

New study reveals 75% of critically ill patients in Latin America are malnourished

A study conducted by German healthcare company Fresenius Kabi has revealed that more than 75% of critically ill patients in Latin American hospitals are either malnourished or at risk of becoming malnourished.

GSK submits biologics licence application to FDA for shingles vaccine

GlaxoSmithKline (GSK) has submitted a biologics licence application to the US Food and Drug Administration (FDA) for approval of its candidate shingles vaccine, Shingrix, to help prevent herpes zoster (shingles) in people aged 50 years or more.

HMT to support NIA’s study on brain metabolomic profiles in Alzheimer’s

Human Metabolome Technologies (HMT) has been contracted by the National Institute on Aging (NIA) to study brain metabolomic profiles in Alzheimer’s disease.

UK researchers explore use of nanotechnology to improve HIV drug therapies

Researchers at the University of Liverpool, UK, are exploring the use of nanotechnology to improve administration and availability of drug therapies to HIV patients.

Elsevier selects four start-up companies for The Hive incubator project

Elsevier has selected four start-up companies for its new incubator project, The Hive, for biotech and pharmaceutical start-up firms.

Milo Biotechnology receives orphan drug designation for AAV1-FS344 to treat inclusion body myositis

Milo Biotechnology has secured Orphan Drug designation for its AAV1-FS344 from the Federal Drug Administration’s (FDA) Office of Orphan Products Development for treatment of inclusion body myositis.